

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER POR PATENTS PO Box (430) Alexandria, Virginia 22313-1450 www.orupo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/715,591	11/18/2003	Janos Pato	AXM-012.3 US	4727
7590 04/15/2008 Leon R. Yankwich			EXAMINER	
YANKWICH & ASSOCIATES 201 Broadway Cambridge, MA 02139			SWARTZ, RODNEY P	
			ART UNIT	PAPER NUMBER
0 /			1645	
			MAIL DATE	DELIVERY MODE
			04/15/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/715.591 PATO ET AL. Office Action Summary Examiner Art Unit Rodney P. Swartz, Ph.D. 1645 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 27 December 2008. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-23 is/are pending in the application. 4a) Of the above claim(s) 1-12 and 16-23 is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) 13-15 is/are rejected. 7) Claim(s) _____ is/are objected to. 8) Claim(s) 1-23 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. Attachment(s) 1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413)

Notice of Draftsperson's Patent Drawing Review (PTO-948)

Information Disclosure Statement(s) (PTO/S5/08)
 Paper No(s)/Mail Date ______.

Paper No(s)/Mail Date.

6) Other:

Notice of Informal Patent Application

Application/Control Number: 10/715,591 Page 2

Art Unit: 1645

DETAILED ACTION

Applicants' Response to Office Action, received 27 December 2007, is acknowledged.

Claim 13 has been amended.

2. Claims 1-23 are pending. Claims 1-12 and 16-23 are withdrawn from further

consideration pursuant to 37 CFR 1.142(b), as being drawn to a nonelected invention.

3. Claims 13-15, drawn to compound 237, i.e., 2-(cyclopropanecarbonyl-amino)-4,5,6,7-

tetrahydro-benzo[b]thiophene-3-carbosylic acid amide are under consideration.

Rejections Withdrawn

 The rejection of claims 14 and 15 under 35 U.S.C. 112, second paragraph, as being indefinite for "pharmaceutical" composition, is withdrawn.

Rejections Maintained

 The rejection of claims 13-15 under 35 U.S.C. 112, first paragraph, scope of enablement for the extremely broad scope of inhibitors of any/all serine/threonine kinases of any/all other species of mycobacteria, is maintained.

Applicants argue that the amendment of claim 13 obviates the rejection because the claims are now drawn to compounds which are inhibitors of mycobacterial serine/threonine protein kinase G (PknG).

The examiner has considered applicants' argument, but does not find it persuasive because the claims, as newly amended, are not drawn to inhibitors of mycobacterial serine/threonine protein kinase G (PknG), but to a mycobacterial serine/threonine protein kinase inhibitor G compound.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

Application/Control Number: 10/715,591

Art Unit: 1645

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

7. As newly amended, claims 13-15 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Newly amended claim 13 now recites: "A mycobacterial serine/threonine protein kinase inhibitor G (PknG) compound have the general formula (1):".

It is unclear if the claim is drawn to a compound which is an inhibitor of protein kinase G, or a compound which is a 'protein kinase inhibitor G". If it is the latter, the examiner requires further explanation on what is a "protein kinase inhibitor G".

Conclusion

- No claims are allowed.
- Applicant's amendment necessitated the new ground(s) of rejection presented in this
 Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a).
 Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Art Unit: 1645

10. This application contains claims 1-12 and 16-23 drawn to a nonelected invention. A complete reply to the final rejection must include cancellation of nonelected claims or other appropriate action (37 CFR 1.144) See MPEP § 821.01.

11. Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Rodney P. Swartz, Ph.D., Art Unit 1645, whose telephone number is (571) 272-0865. The examiner can normally be reached on Monday through Wednesday from 9:00 AM to 7:30 PM EST. Thursday is the examiner's work at home day.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's Supervisor, Shannon Foley, can be reached on (571)272-0898.

The fax phone number for the organization where this application or proceeding is assigned is (571) 273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rodney P. Swartz, Ph.D./ Primary Examiner, Art Unit 1645

April 14, 2008